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sient transfection of CXCR1 and CXCR2 neither augmented 
the transepithelial migration of neutrophils, nor did the se-
lective blockade of CXCR1 and CXCR2 have any significant 
effect on neutrophilic transepithelial migration. In addition, 
no differences were found in PBECs and neutrophils derived 
from healthy controls and COPD patients.  Conclusions: The 
data of the present study do not support the hypothesis that 
bronchoepithelial expression of CXCR1 and/or CXCR2 facili-
tate transepithelial migration of neutrophils. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 The pathophysiology of chronic obstructive pulmo-
nary disease (COPD) includes persistent inflammation 
of the airways and lung parenchyma, which is caused by 
an abnormal response of the lung to noxious gases and 
inhaled particles  [1] . Typically, the cellular composition 
of the airway infiltrates consists of neutrophils, macro-
phages, and CD8+ T cells  [1, 2] . There is convincing evi-
dence that neutrophils are one of the primary effector 
cells in COPD  [3–7] . The number of neutrophils is in-
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 Abstract 
 Background: Neutrophilic airway inflammation is one of the 
key features of chronic obstructive pulmonary disease 
(COPD). The chemokine receptors 1 (CXCR1) and 2 (CXCR2) 
are expressed in the bronchial mucosa during chronic in-
flammation and might be of importance for transepithelial 
migration of neutrophils.  Objectives: This study addressed 
the role of bronchoepithelial CXCR1 and CXCR2 expression 
with respect to transepithelial migration of neutrophils. 
 Methods: Primary bronchial epithelial cells (PBECs) derived 
from COPD patients and healthy controls as well as transient-
ly CXCR1- and CXCR2-transfected Calu-6 cells were used for 
transepithelial migration assays of neutrophils under vari-
ous conditions. Epithelial CXCR1 and CXCR2 expression was 
verified by means of flow cytometry.  Results: Transepithelial 
migration of neutrophils was significantly increased follow-
ing lipopolysaccharide pretreatment of epithelial cells. Tran-
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creased in bronchoalveolar lavage fluid as well as in in-
duced sputum samples and airways from COPD patients 
 [6, 8, 9] . The amount of neutrophils correlates with dis-
ease severity and progression in these patients  [3, 8] . 
Neutrophil recruitment to the airways is induced by che-
motactic factors such as CXC ligand 8 (CXCL8) and 
leuko triene B 4 (LTB 4 ), and both mediators are often el-
evated in the airways of patients with COPD  [10–13] . In 
addition, neutrophils were predominant in the airway 
lumen, but a lack of increase in these cells in the subepi-
thelium can be noted in bronchial biopsies of COPD pa-
tients  [14] . This observation may be due to accelerated 
transepithelial migration of neutrophils from the circu-
lation into the airway lumen, although this has not been 
investigated in detail. It is well known that increased 
LTB 4 and CXCL8 levels derive from alveolar macro-
phages and epithelial cells, respectively. This, however, 
should also result in increased levels of neutrophils in the 
subepithelium, which is not the case, and points towards 
potential local mechanisms that facilitate and regulate 
transepithelial migration of neutrophils to the site of in-
flammation.
 CXCL8 and other neutrophil chemoattractants belong 
to the ELR-CXC chemokines, which are ligands of the 
CXC chemokine receptor 1 (CXCR1) or 2 (CXCR2). 
CXCR1 is the receptor for CXCL8 and CXCL6 (granulo-
cyte chemoattractant protein-2), and CXCR2 binds these 
as well as all other ELR-CXC chemokines; CXCL8 binds 
with high affinity to both receptors, while the others are 
ligands of lower affinity  [15–18] . Recent studies focusing 
on urinary tract infections demonstrated that transepi-
thelial neutrophil migration is CXCR1 dependent in vitro 
and defective in CXCR1-knockout mice  [19] . Along this 
line, it was hypothesized that CXCR1 and CXCR2 expres-
sion on bronchial epithelial cells is relevant for the inter-
action between neutrophils and the airway mucosal bar-
rier. It was speculated that these receptors are of impor-
tance for neutrophil migration across airway epithelial 
layers, and, consequently, a potential future therapeutic 
target for the treatment of neutrophilic airway inflamma-
tion, e.g. in COPD patients.
 Materials and Methods 
 Flow Cytometry 
 CXCR1 and CXCR2 receptor proteins were detected on the 
cell surface of primary cells and cell lines using specific antibod-
ies (anti-CXCR1 R&D Systems, MAB330, and anti-CXCR2 R&D 
Systems, MAB331). Primary cells or transfected cell lines were 
harvested and washed once and resuspended in PBS. Specific pri-
mary antibodies were added (1: 50) and the suspension was incu-
bated for 30 min on ice. After additional washing with PBS, la-
beled secondary antibodies were added to the suspension (1: 50). 
The suspension was incubated for 30 min at 4  °  C in the dark. Af-
ter incubation, cells were washed in PBS and resuspended in PBS 
prior to analysis. Fluorescence was measured with a BD FACS-
Calibur flow cytometer (BD, Franklin Lakes, N.J., USA) using a 
488-nm excitation laser. The number of cells stained was calcu-
lated using CellQuest software (BD).
 Cloning of CXCR1 and CXCR2 and Transfection of Calu-6 
Cells 
 For transient and stable transfection, the coding sequences of 
CXCR1 and CXCR2 were cloned in the pDSred-N1 backbone 
(Clontech, Mountain View, Calif., USA) or pcGFP-N1 (Clontech). 
The coding sequences from CXCR1 (NM_000634.2) and CXCR2 
(NM_001557.3) were amplified using CXCR1_fw 5  -GCTAGC-
GCTGAAACTGAAGAGGACATG-3  and CXCR1_rev 5  -CTC-
GAGGTTGGAAGAGACATTGACA-3  with attached  Nhe I and 
 Xho I restriction sites. A specific CXCR2 sequence was amplified 
using CXCR2_fw 5  -CTCGAGAGTAGTGGAAGTGTGCC-3  
and CXCR2_rev 5  -CTCGAGAGTAGTGGAAGTGTGCC-3  
with attached  Nhe I and  Xho I restriction sites. cDNA from neutro-
philic granulocytes served as template DNA. Amplicons were 
subcloned into the pCR2.1 backbone using the TOPO-Cloning kit 
(Invitrogen, Darmstadt, Germany). After digestion with  Nhe I 
and  Xho I, the fragments were cloned into the expression vectors. 
The vectors are named CXCR1-pDSred-N1 and CXCR2-pcGFP-
N1. The accuracy of inserts was checked by sequencing.
 For transient overexpression of CXCR1 and CXCR2, Calu-6 
cells were transfected with the CXCR1-pDSred-N1 and CXCR2-
pcGFP-N1. After reaching 80% confluency, cells were transfected 
with 4   g plasmid DNA in a cell culture flask. DNA was mixed in 
a 1: 2 ratio with FuGENE6 transfection reagent (Roche, Mannheim, 
Germany). After 30 min of incubation in serum-free media, the 
mix was added to the cells. After 24 h, cells were checked for 
CXCR1 and CXCR2 expression using flow cytometry. Positive 
cells were used for transmigration assays.
 Granulocyte Isolation 
 Informed consent was obtained from all patients and healthy 
volunteers according to the procedures approved by the local eth-
ics committee. Neutrophilic granulocytes were isolated from 
healthy volunteers and COPD patients; 20 ml of whole blood was 
transferred to a dextran gradient [18 ml Deltadex 60 (DeltaSelect) 
plus 2 ml citrate dextrose solution; Sigma, Taufenkirchen, Ger-
many]. Erythrocytes were removed by centrifugation. The super-
natant containing lymphocytes and sera was transferred to 20 ml 
Ficoll (Ficoll-Paque Plus). After 20 min of centrifugation at 600  g 
(no break), the neutrophilic granulocytes were at the bottom of 
the gradient. The supernatant containing the plasma and lym-
phocytes was removed. Remaining erythrocytes were removed 
from the pellet with erythrocyte lysis buffer (Buffer EL; Qiagen, 
Hilden, Germany) plus a 5-min incubation at 4  °  C and centrifuga-
tion. The neutrophilic granulocytes were resuspended in normal 
growth media. Cell numbers were determined using trypan blue 
exclusion (Sigma) and a Neubauer chamber.
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 Transmigration Assay 
 To test granulocyte migration, transmigration assays were 
performed. Tissue culture (TC) inserts with 3.0-  m pore size 
(Greiner Bio-One, Frickenhausen, Germany) were coated with rat 
tail collagen I (Sigma-Aldrich). CXCR1- and CXCR2-positive 
Calu-6 cells were seeded on the outer side of the TC insert mem-
brane, which represents the apical side in the migration assays. 
The TC inserts were placed into 24-well plates filled with normal 
growth media (Calu-6 medium). A volt ohmmeter (World Preci-
sion Instruments, Berlin, Germany) was used to verify the tight-
ness of the cell layer; 12 h before the assay, half of the TC inserts 
were pretreated from the apical side with 5   g/ml lipopolysaccha-
ride (LPS; source:  Escherichia coli 055:B5; Sigma-Aldrich). LPS 
was removed completely before the migration assay was per-
formed. Isolated granulocytes (250,000) were added to the basal 
side of each TC insert membrane. After 3 h of incubation at 37  °  C, 
the TC inserts were removed from the wells. The remaining 
growth medium was transferred to fresh cups. The number of 
migrated cells was assessed using the CyQuant Cell Proliferation 
Kit (Invitrogen, Darmstadt, Germany) according to the manufac-
turer’s protocol. Specific antibodies (anti-CXCR1 R&D Systems, 
MAB330, and anti-CXCR2 R&D Systems, MAB331) were used to 
block the receptors. Antibodies were applied 12 h before the assay 
was performed to the apical side of the TC inserts. The assay an-
tibodies had been completely removed in advance. Untransfected 
Calu-6 cells or naive primary bronchial epithelial cells (PBECs) 
served as controls. Experiments were performed twice for each 
condition and granulocyte isolation.
 Subjects 
 Patients who were referred to our clinic for flexible bronchos-
copy for various reasons were screened to be included in the pres-
ent study. Selection of COPD patients was based on the definition 
and classification given by the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD)  [1] . In brief, the following inclu-
sion criteria had to be met: stable airflow limitation, FEV 1  ! 70% 
of predicted, reversibility  ! 10% of predicted FEV 1 after 200   g 
inhaled salbutamol and a smoking history of  1 10 pack years. 
None of the patients with COPD had a history of atopy or evidence 
of atopy on skin prick testing for common aeroallergens. Control 
subjects were nonsmokers with normal lung function and no his-
tory of airway disease. Exclusion criteria were a history of respira-
tory tract infection or exacerbation of airway disease within the 
previous 8 weeks, and systemic or topic corticosteroid treatment 
during the previous 12 weeks. All patients gave written informed 
consent, and the study was approved by the local ethics commit-
tee (approval No. 03/180).
 Patients underwent fiberoptic bronchoscopy under light seda-
tion. Bronchial epithelium was obtained by gentle brushing of 
segmental and subsegmental bronchi under direct visual guid-
ance by means of a protected brush. Each patient had 20–30 
brushes of the bronchial epithelium. Brushing was accomplished 
by a very light gliding along the surfaces of the airways. Brushes 
were immediately placed in ice-cold bronchial epithelial growth 
medium and transported directly to the laboratory for further 
processing.
 Culture of PBECs 
 Brushes were vortexed vigorously, and the cell suspension har-
vested was filtered through a 200-  m filter (Millipore; Billerica, 
Mass., USA) to remove mucus and cellular debris, and then treat-
ed with 4.8 U/ml Dispase II (Roche, Mannheim, Germany) to 
eliminate cell clumping. The cells were then centrifuged at 150  g 
for 10 min, and the pellet was resuspended in cell culture medium. 
Cells were counted using a hemocytometer. Cell viability was de-
termined by trypan blue exclusion. Cells were resuspended in se-
rum-free bronchial epithelial cell growth medium (Promocell, 
Freiburg, Germany) supplemented with a variety of growth fac-
tors, including bovine pituitary extract (0.052 mg/ml), recombi-
nant human epidermal growth factor (0.5 ng/ml), insulin (5   g/
ml), hydrocortisone (0.5   g/ml), epinephrine (0.5   g/ml), triio-
dothyronine (6.5 ng/ml), transferrin (0.01 mg/ml) and retinoic 
acid (0.1 ng/ml). In addition, the medium contained penicillin G 
(100 U/ml), streptomycin (100   g/ml) and amphotericin B (0.25 
  g/ml; Invitrogen, Darmstadt, Germany). Cultures were main-
tained in a humidified atmosphere at 37  °  C in air/carbon dioxide 
(95/5% vol/vol). The identity of the epithelial cells was confirmed 
in all cultures by light microscopy and in randomly selected cul-
tures by immunocytochemical staining for cytokeratin expres-
sion using a pancytokeratin antibody (clone KL1) directed against 
cytokeratin types 1, 2, 5–8, 11, 14, 16, and 18 (Immunotec, Marl, 
Germany). The monoclonal antifibroblast antibody FibAS02
(Dianova, Hamburg, Germany) was used to exclude contamina-
tion by fibroblasts  [20] . The staining was performed according to 
Kunz-Schughart et al.  [21] , as described in detail previously. In 
general, cell culture experiments were performed after the first 
passage and no higher passage cell cultures were used.
 Calu-6 Cell Culture 
 Calu-6 cells (human lung fibroblasts) were maintained in 
MEM with EBSS and  L -glutamine (PAN Biotech) supplemented 
with sodium pyruvate, non-essential amino acids (1 m M ; Bio-
chrome, Berlin, Germany), penicillin (50 U/ml), streptomycin (50 
  g/ml) and 10% FCS (PAA Laboratories, Pasching, Austria). Cells 
were grown at 37  °  C in humidified air with 5% CO 2 .
 Statistical Analysis 
 For statistical analyses, the Kruskal-Wallis rank sum test was 
used to compare data between groups, followed by the Mann-
Whitney rank sum test using SigmaStat for Windows V2.03. Dif-
ferences were considered to be statistically different if p  ! 0.05. 
x-fold migration was calculated for each value compared to the 
mean of the control group.
 Results 
 Subjects 
 Nine COPD and 21 control subjects without airflow 
limitation were included in the study. All patients were 
referred for bronchoscopy for clinical reasons. All pa-
tients underwent preoperative diagnostic procedures for 
suspected peripheral or central carcinoma of the bron-
chus. In addition, based on the patients’ history and files, 
no other conditions known or suggested to be associated 
with altered immune responses were detected. In par-
ticular, no signs of diabetes, rheumatoid arthritis, in-
 CXCR1 and CXCR2 and Bronchial 
Epithelial Cells 
Respiration 2012;84:108–116 111
flammatory bowel diseases, or myeloproliferative syn-
dromes were found. The COPD patients were classified 
as stage I (n = 3), stage II (n = 2), stage III (n = 1) and 
stage IV (n = 3) based on the GOLD classification  [1] . All 
were exsmokers and aged between 45 and 70 years. 
COPD patients were clinically stable for at least 8 weeks 
prior to bronchoscopy without any changes in medica-
tion. Control subjects, aged between 42 and 68 years, 
had no evidence of chronic disease and were free of med-
ication.
100
100
101
102
103
104
101 102 103
CXCR1a
FS
C-
he
ig
ht
104
100
100
101
102
103
104
101 102 103
CXCR2c
FS
C-
he
ig
ht
104
100
100
101
102
103
104
101 102 103
Unstainede
FS
C-
he
ig
ht
104
100
100
101
102
103
104
101 102 103
ISOg
FS
C-
he
ig
ht
104
Quad Events % Gated
UL
UR
LL
LR
0
0
4,013
6,102
0.00
0.00
39.67
60.33
100
0
1,000
101 102 103
CXCR1b
FS
C-
he
ig
ht
104
Quad Events % Gated
UL
UR
LL
LR
0
0
16,731
9,712
0.00
0.00
63.27
36.73
100
0
1,000
101 102 103
CXCR2d
FS
C-
he
ig
ht
104
Quad Events % Gated
UL
UR
LL
LR
1
0
24,314
976
0.00
0.00
96.14
3.86
100
0
1,000
101 102 103
Unstained
020407.001
f
FS
C-
he
ig
ht
104
Quad Events % Gated
UL
UR
LL
LR
0
0
22,742
4
0.00
0.00
99.98
0.02
100
0
1,000
101 102 103
ISOh
FS
C-
he
ig
ht
104
Quad Events % Gated
UL
UR
LL
LR
1
0
23,033
9
0.00
0.00
99.96
0.04
Quad Events % Gated
UL
UR
LL
LR
0
0
9,787
336
0.00
0.00
96.68
3.32
Quad Events % Gated
UL
UR
LL
LR
0
0
10,101
17
0.00
0.00
99.83
0.17
Quad Events % Gated
UL
UR
LL
LR
0
0
9,986
96
0.00
0.00
99.05
0.95
 Fig. 1. Representative FACS analyses of CXCR1 ( a ,  b ) and CXCR2 ( c ,  d ) expression on the surface of naive PBECs 
from a COPD patient ( a ,  c ,  e ,  g ) and a non-COPD donor ( b ,  d ,  f ,  h ). Note that there is an even higher expres-
sion of CXCR1 in PBECs in both cases. Isotype staining (ISO) and unstained cells served as controls.
FSC = Forward scatter; Quad = quadrant; UL = upper left; UR = upper right; LL = lower left; LR = lower right. 
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 Surface Expression of CXCR1 and CXCR2 
 First we confirmed the expression of CXCR1 and 
CXCR2 on the surface of PBECs using flow cytometry. 
PBECs from COPD patients and controls (non-COPD 
patients) were stained for CXCR1 and CXCR2 using spe-
cific antibodies. In  figure 1 a, c, representative FACS anal-
yses are shown. On PBECs from COPD patients, expres-
sion of CXCR1 was increased compared to CXCR2 ex-
pression on PBECs: 60% of PBECs analyzed were positive 
for CXCR1 whereas only 3% of the cells were CXCR2 pos-
itive. In PBECs from control patients, 37% of the cells ex-
pressed CXCR1, whereas CXCR2 expression amounted 
to 3%. All of the PBECs showed similar mean fluores-
cence intensity ratios; the calculated ratio for CXCR1 on 
PBECs was 22.92 (control 1) and 25.53 (control 2) com-
pared to 26.1 on PBECs from a COPD patient. For CXCR2, 
the respective ratios were 4.26 (control 1) and 4.53 (con-
trol 2) compared to 4.82 (COPD patient).
 Surface Expression of CXCR1 and CXCR2 in Calu-6 
Cells following Transient Transfection 
 Calu-6 cells were transiently transfected with CXCR1 
or CXCR2 expression vectors. Before using these cells in 
the migration assay, surface expression of CXCR1 and 
CXCR2 was confirmed by means of FACS analysis. The 
analysis was performed three times with cells from inde-
pendent transfections with similar results. In  figure 2 , 
representative FACS analyses of the expression of both 
receptors on naive Calu-6 and following transient trans-
fection are shown. Naive Calu-6 cells show neither 
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 Fig. 2. Representative FACS analysis of CXCR1 and CXCR2 expression on the surface of Calu-6 cells following 
transient transfection.  a ,  c CXCR1 and CXCR2 expression on untransfected Calu-6 cells. b ,  d CXCR1 and 
CXCR2 expression after transient transfection. Note that no expression was detected on naive Calu-6 cells. Iso-
type staining (ISO;  e ) and unstained cells ( f ) served as controls. FSC = Forward scatter; Quad = quadrant;
UL = upper left; UR = upper right; LL = lower left; LR = lower right. 
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CXCR1 nor CXCR2 expression ( fig.  2 a, c). CXCR1 ex-
pression was higher on the Calu-6 cells compared to 
CXCR2. After transient transfection, 40% of the Calu-6 
cells showed CXCR1 expression, with 18% of the cells 
showing CXCR2 expression. This expression pattern is 
comparable with the expression on the surface of naive 
PBECs. Subsequently, the transiently transfected Calu-6 
cells were used in transmigration assays in combination 
with neutrophilic granulocytes from either healthy con-
trols or COPD patients.
 Transmigration Assays of Neutrophilic Granulocytes 
in Combination with Transiently CXCR1- and 
CXCR2-Transfected Calu-6 Cells 
 The resistance of the transiently transfected Calu-6 
cell layer was measured using a voltmeter to confirm the 
tightness of the cell layer (data not shown). Neutrophilic 
granulocytes from COPD patients or healthy volunteers 
were added to the basal side of the transfected cells and 
cocultured for 3 h. In  figure 3 , the x-fold migration of 
neutrophils from control patients is shown. LPS stimula-
tion significantly increased the transmigration of neutro-
phils resulting in a 1.4-fold (range 1.05–1.87) increase. 
Similar findings were seen for CXCR1 overexpression 
following LPS stimulation (1.3-fold; range 1.08–2.11) and 
unstimulated conditions. For CXCR2, transmigration of 
neutrophils was significantly lower following LPS treat-
ment (median = 0.98; range 0.89–1.48) compared to con-
trol cells and unstimulated conditions. When neutro-
phils from COPD patients were used instead, no signifi-
cant increase in the transmigration of neutrophils was 
observed with respect to CXCR1 and CXCR2 overexpres-
sion under either condition ( fig. 4 ). In summary, as shown 
in  figures 3 and  4 , there is no augmentation in the migra-
tion of neutrophilic granulocytes from either healthy do-
nors or COPD patients following CXCR1 and CXCR2 
overexpression.
 Transmigration Assays of Neutrophilic Granulocytes 
Using PBECs 
 PBECs derived from control subjects and COPD pa-
tients were used in combination with neutrophils from 
healthy controls and COPD patients to perform transmi-
gration assays in both the absence and presence of spe-
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cific CXCR1 and CXCR2 antibodies. The antibodies were 
applied to PBECs 12 h prior to incubation with neutro-
philic granulocytes.
 As shown in  figure 5 a, LPS stimulation of PBECs de-
rived from non-COPD patients resulted in a 1.9-fold (me-
dian = 1.89, range 0.24–4.70) increase in transepithelial 
migration of neutrophils. In the presence of anti-CXCR1 
and anti-CXCR2 antibodies, the increase in LPS-stimu-
lated transepithelial migration of neutrophils derived 
from control subjects was 1.5-fold (range 0.62–3.26; non-
significant compared to LPS stimulation). In the presence 
of anti-CXCR1 or anti-CXCR2, the increase was 1.9-fold 
(range 0.88–3.42) and 1.08-fold (range 1.0–1.14), respec-
tively (data not shown).
 Similar results ( fig. 5 b) were obtained when PBECs de-
rived from COPD patients were used. LPS stimulation 
resulted in a 1.8-fold (range 0.88–4.62) increase in the 
transmigration of neutrophils derived from COPD pa-
tients (p  ! 0.05 vs. unstimulated control). Blockade of 
both receptors revealed a 2.1-fold increase in the trans-
epithelial migration of neutrophils (range 1.47–3.13; non-
significant compared to LPS stimulation), whereas a 1.4-
fold (range 1.22–1.96) increase for CXCR1 and a 2.1-fold 
(range 1.47–3.13) increase were observed when only 
CXCR1 or CXCR2 were blocked (data not shown).
 Figure 5 summarizes the results demonstrating that 
the CXCR1 and/or CXCR2 blockade had no significant 
effect on transepithelial migration of neutrophilic granu-
locytes under either condition.
 Discussion 
 In the present report, the potentially CXCR1- and 
CXCR2-dependent transepithelial migration of neutro-
phils was investigated by using different cell culture mod-
els as well as airway epithelial cell lines and PBECs de-
rived from healthy nonsmokers and COPD patients. 
Recent studies suggest an accelerated transepithelial 
migration of neutrophils from the circulation to the air-
way lumen, which could, at least in part, explain why air-
way inflammation dominated by neutrophils is often 
found in COPD patients.
 Significant CXCR1 and CXCR2 expression has al-
ready been demonstrated in bronchial epithelial cells 
 [22–24] . Qiu et al.  [23] showed upregulation of epithelial 
CXCR2 mRNA expression in COPD patients with severe 
exacerbation. However, in the same paper, neither in sta-
ble COPD patients nor in patients with severe COPD ex-
acerbation CXCR1 expression was detected. In a more 
recent paper, a robust bronchoepithelial expression of 
both receptors was seen in COPD patients across all stag-
es of severity  [22] . This is in line with the results of the 
present study demonstrating cell surface expression of 
CXCR1 and CXCR2 in PBECs from healthy donors and 
COPD patients, respectively. Therefore, it is evident that 
the bronchial mucosa expresses both chemokine recep-
tors, which may be involved in the transepithelial migra-
tion of neutrophils.
 Godaly et al.  [19] were able to demonstrate that the ex-
pression of functional IL-8 receptors is crucial for neutro-
phils to cross the epithelial barrier. This was shown in 
IL-8 receptor-knockout mice with urinary tract infection 
as well as in human uroepithelial cell lines. In addition, it 
was speculated that IL-8 dimer formation, which is re-
quired for IL-8 receptor activation, forms a bridge be-
tween the neutrophils and the epithelial cells, thereby en-
abling transepithelial cell migration. This hypothesis was 
supported by a recently published paper using molecular 
dynamic simulations, thereby showing that electrostatic 
interactions are favorable for CXCL8 homodimer forma-
tion, which could have substantial consequences biologi-
cally  [25] .
 However, the results of the present study do not rein-
force this view with respect to the transepithelial migra-
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 Fig. 5.  a Transmigration assay of neutrophilic granulocytes from 
healthy donors in combination with blocking of CXCR1 and 
CXCR2 in PBECs isolated from healthy donors (control n = 33; 
LPS n = 35; aCXCR1 + aCXCR2 + LPS n = 14).  b Transmigration 
assay of neutrophilic granulocytes from COPD patients in com-
bination with blocking of CXCR1 and CXCR2 in PBECs isolat -
ed from COPD patients (control n = 23; LPS n = 24; aCXCR1 + 
aCXCR2 + LPS n = 7). x-fold migration of the neutrophilic granu-
locytes after 3 h of coculture. For further information, see legend 
to figures 3, 4. aCXCR1 = Anti-CXCR1; aCXCR2 = anti-CXCR2. 
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tion of neutrophils across the bronchoepithelial barrier. 
Different experimental approaches were realized to sub-
stantiate the hypothesis. Transient CXCR1 and CXCR2 
transfections of Calu-6 cells, neither of which express 
CXCR1 or CXCR2 in the control situation, were per-
formed and used for transmigration experiments. In ad-
dition, PBECs from healthy nonsmokers and COPD pa-
tients, with confirmed IL-8 receptor expression, as well 
as neutrophils from both cohorts were differentially ap-
plied for migration assays. Anti-CXCR1 and anti-CXCR2 
control experiments confirmed the negative results 
found. Therefore, several lines of evidence were generated 
demonstrating that the migration of neutrophils through 
airway epithelial cell layers is not controlled and/or fa-
cilitated by CXCR1 and CXCR2 expression.
 Based on the results presented here and available data 
in the literature, the effects of CXCR1 and CXCR2 on re-
spiratory epithelial cells remain obscure. According to 
the evidence presented for IL-8 receptor-expressing in-
testinal epithelial cells, one might speculate that CXCR1 
and/or CXCR2 play an important role in the mainte-
nance of the mucosal epithelial surface barrier, thus af-
fecting the infiltration of inflammatory cells into the host 
that may maintain airway inflammation. This was at 
least demonstrated in an in vitro migration model using 
intestinal Caco-2 and HT-29 cells  [26] . Whether the same 
holds true for respiratory epithelial cells requires further 
investigation and was beyond the scope of the present 
study.
 Neutrophil recruitment during COPD exacerbations 
appears to be partially mediated by the two impor-
tant neutrophil chemoattractants CXCL5 (ENA-78) and 
CXCL8 (IL-8). Upregulation of their receptors, CXCR1 
and CXCR2, has been observed in bronchial biopsy spec-
imens in severe COPD exacerbations  [23] , which is in line 
with our results. In addition, CXCR1 and CXCR2 are ex-
pressed on a broad range of leukocytes, most notably neu-
trophilic granulocytes. The physiological role of these re-
ceptors is mediating neutrophil recruitment, which has 
been described in humans as well as in primates, rodents 
and rabbits. Recent data provide evidence that the expres-
sion of CXCR1 and CXCR2 in neutrophils is maintained 
in COPD patients when compared to healthy controls or 
healthy smokers, indicating that COPD per se does not 
alter the expression of chemoattractant receptors  [27] .
 Importantly, treatment with a CXCR2 antagonist 
(SCH527123) blocked pulmonary neutrophilia associat-
ed with the repeat bronchoscopy procedure  [28] , suggest-
ing that CXCR2 inhibition is important for the inflam-
matory events occurring in the distal lungs of human 
COPD patients. Similar results were found in ozone-in-
duced neutrophil recruitment to the lungs in healthy hu-
mans  [29] . Thus, there is overwhelming evidence that 
IL-8 receptor expression on neutrophils is important for 
the development of the neutrophilic lung inflammation 
present in COPD. The aforementioned studies in animals 
and humans have clearly demonstrated that CXCR1/
CXCR2 antagonism inhibits pulmonary and airway neu-
trophilia  [28, 29] . Since the present study shows that the 
blockade of bronchoepithelial CXCR1/CXCR2 expres-
sion has no impact on transepithelial neutrophil migra-
tion, the important site of CXCR1/CXCR2 blockade has 
to be the neutrophil itself. This hypothesis is further sup-
ported by the observation that the CXCR2 antagonist 
SCH527123 reversibly decreases peripheral neutrophil 
counts in humans. This implies that the CXCR2 antago-
nism inhibits neutrophil egress from the bone marrow 
and migration from peripheral blood to tissue  [29] . Neu-
trophils are generated in large numbers in the bone mar-
row; mature neutrophils circulate in the bloodstream for 
several hours and are recruited to tissues and sites of in-
fection via a multistep process  [30, 31] . There is convinc-
ing evidence that the mechanisms of neutrophilic traf-
ficking are complex and probably disease and stimulus 
specific in connection with a certain degree of redun-
dancy in the mechanisms involved  [30] . To further ad-
dress this issue in the future, it would be important to use 
disease-specific models in conjunction with disease- and 
phenotype-specific neutrophils.
 There are some limitations of the present study. First-
ly, the data presented are from in vitro cell culture ex-
periments, which do not necessarily reflect the complex 
in vivo situation seen in COPD patients. Secondly, CXCR1 
and CXCR2 expression of neutrophils was not assessed 
on a regular basis before each experiment. Although un-
likely, this could also have influenced our results.
 In summary, the present study generated substantial 
evidence indicating that airway epithelial expression of 
both IL-8 receptors CXCR1 and CXCR2 does not facili-
tate transepithelial migration of neutrophilic granulo-
cytes. This, however, does not contradict the importance 
of CXCR1 and CXCR2 in neutrophilic lung inflamma-
tion when expressed on polymorphonuclear granulo-
cytes.
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